SOSayo Okamoto

Sayo Okamoto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sayo Okamoto has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Chikao Morimoto

    Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo 113-8421, Japan

    1 shared publication
  • Eriko Komiya

    Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University , Tokyo , Japan

    1 shared publication
  • Haruna Otsuka

    Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University , Tokyo , Japan

    1 shared publication
  • Kei Ohnuma

    Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University , Tokyo , Japan

    1 shared publication
  • Kyoko Kuwahara-Arai

    Department of Microbiology, Juntendo University School of Medicine , Tokyo , Japan

    1 shared publication
  • Nam H. Dang

    Division of Hematology/Oncology, University of Florida , Gainesville , FL , USA

    1 shared publication

Latest Publications

  • Characterization of novel anti-IL-26 neutralizing monoclonal antibodies for the treatment of inflammatory diseases including psoriasis

    by Ryo Hatano, Takumi Itoh, Haruna Otsuka, Sayo Okamoto, Eriko Komiya, Satoshi Iwata, Thomas M. Aune, Nam H. Dang, Kyoko Kuwahara-Arai, Kei Ohnuma, et al.

    Interleukin (IL)-26, known as a Th17 cytokine, acts on various cell types and has multiple biological functions. Although its precise role still remains to be elucidated, IL-26 is suggested to be associated with the pathology of diverse chronic inflammatory diseases such as psoriasis, inflammatory bowel diseases and rheumatoid arthritis. To develop novel neutralizing anti-human IL-26 monoclonal antibodies (mAbs) for therapeutic use in the clinical setting, we immunized mice with human IL-26 protein. Hybridomas producing anti-IL-26 mAbs were screened for various in vitro functional assays, STAT3 phosphorylation and antibiotic assays. Although the IL-20RA/IL-10RB heterodimer is generally believed to be the IL-26 receptor, our data strongly suggest that both IL-20RA-dependent and -independent pathways are involved in IL-26-mediated stimulation. We also investigated the potential therapeutic effect of anti-IL-26 mAbs in the imiquimod-induced psoriasis-like murine model using human IL-26 transgenic mice. These screening methods enabled us to develop novel neutralizing anti-human IL-26 mAbs. Importantly, administration of IL-26-neutralizing mAb did not have an effect on the antimicrobial activity of IL-26. Taken together, our data strongly suggest that our newly developed anti-human IL-26 mAb is a potential therapeutic agent for the treatment of diverse chronic inflammatory diseases including psoriasis.